CA2961745A1 - Novel soluble guanylate cyclase activators and their use - Google Patents

Novel soluble guanylate cyclase activators and their use Download PDF

Info

Publication number
CA2961745A1
CA2961745A1 CA2961745A CA2961745A CA2961745A1 CA 2961745 A1 CA2961745 A1 CA 2961745A1 CA 2961745 A CA2961745 A CA 2961745A CA 2961745 A CA2961745 A CA 2961745A CA 2961745 A1 CA2961745 A1 CA 2961745A1
Authority
CA
Canada
Prior art keywords
pyridin
piperidin
piperidine
carboxylic acid
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2961745A
Other languages
English (en)
French (fr)
Inventor
Anne Marie Jeanne Bouillot
Nerina Dodic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CA2961745A1 publication Critical patent/CA2961745A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
CA2961745A 2014-09-19 2015-09-18 Novel soluble guanylate cyclase activators and their use Abandoned CA2961745A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052537P 2014-09-19 2014-09-19
US62/052,537 2014-09-19
PCT/IB2015/057219 WO2016042536A1 (en) 2014-09-19 2015-09-18 Novel soluble guanylate cyclase activators and their use

Publications (1)

Publication Number Publication Date
CA2961745A1 true CA2961745A1 (en) 2016-03-24

Family

ID=54238488

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2961745A Abandoned CA2961745A1 (en) 2014-09-19 2015-09-18 Novel soluble guanylate cyclase activators and their use

Country Status (21)

Country Link
US (2) US9938260B2 (enExample)
EP (1) EP3194384A1 (enExample)
JP (3) JP6678656B2 (enExample)
KR (1) KR20170054508A (enExample)
CN (1) CN106687456B (enExample)
AU (1) AU2015319724B2 (enExample)
BR (1) BR112017005660A2 (enExample)
CA (1) CA2961745A1 (enExample)
CL (1) CL2017000640A1 (enExample)
CO (1) CO2017002506A2 (enExample)
CR (1) CR20170102A (enExample)
DO (1) DOP2017000073A (enExample)
EA (1) EA033697B1 (enExample)
IL (1) IL251094A0 (enExample)
MA (1) MA40583A (enExample)
MX (1) MX2017003621A (enExample)
PE (1) PE20170937A1 (enExample)
PH (1) PH12017500481A1 (enExample)
SG (1) SG11201701915TA (enExample)
WO (1) WO2016042536A1 (enExample)
ZA (1) ZA201701835B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202400446T1 (it) 2014-02-06 2024-11-15 Nxera Pharma Uk Ltd Composti aza biciclici come agonisti del recettore muscarinico
WO2016042536A1 (en) * 2014-09-19 2016-03-24 Glaxosmithkline Intellectual Property Development Limited Novel soluble guanylate cyclase activators and their use
TN2017000092A1 (en) 2014-09-19 2018-07-04 Bayer Pharma AG Benzyl substituted indazoles as bub1 inhibitors.
CN109890379A (zh) 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
CA3098475A1 (en) 2018-04-30 2019-11-07 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
EA202092680A1 (ru) 2018-05-15 2021-04-13 Байер Акциенгезельшафт 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон
EP3574905A1 (en) 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
EP3911675A1 (en) 2019-01-17 2021-11-24 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
WO2023237577A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602143A (en) 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
KR20140032505A (ko) 2006-11-09 2014-03-14 알콘 리서치, 리미티드 약물 전달용 수불용성 폴리머 매트릭스
PE20091258A1 (es) * 2007-12-03 2009-09-12 Smithkline Beecham Corp Derivados de piridina como activadores de la guanilato ciclasa soluble
WO2010015653A1 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
WO2010099054A2 (en) * 2009-02-26 2010-09-02 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102009012314A1 (de) * 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
JP5636296B2 (ja) 2011-01-20 2014-12-03 公益財団法人微生物化学研究会 塩分含有有機廃液処理剤、並びに、塩分濃度低下剤、塩分含有有機廃液の処理方法、及び包括固定担体
WO2016042536A1 (en) * 2014-09-19 2016-03-24 Glaxosmithkline Intellectual Property Development Limited Novel soluble guanylate cyclase activators and their use

Also Published As

Publication number Publication date
CO2017002506A2 (es) 2017-07-28
DOP2017000073A (es) 2017-04-16
ZA201701835B (en) 2018-12-19
PH12017500481A1 (en) 2017-08-07
EP3194384A1 (en) 2017-07-26
CN106687456B (zh) 2019-12-03
US10472350B2 (en) 2019-11-12
MX2017003621A (es) 2017-07-14
JP2021155450A (ja) 2021-10-07
AU2015319724B2 (en) 2018-05-10
PE20170937A1 (es) 2017-07-13
JP2017527602A (ja) 2017-09-21
WO2016042536A1 (en) 2016-03-24
MA40583A (fr) 2016-03-24
JP6908747B2 (ja) 2021-07-28
EA201790655A1 (ru) 2017-08-31
US9938260B2 (en) 2018-04-10
KR20170054508A (ko) 2017-05-17
CR20170102A (es) 2017-07-17
JP6678656B2 (ja) 2020-04-08
US20170305888A1 (en) 2017-10-26
EA033697B1 (ru) 2019-11-18
CL2017000640A1 (es) 2017-10-06
US20180194756A1 (en) 2018-07-12
IL251094A0 (en) 2017-04-30
AU2015319724A1 (en) 2017-04-06
CN106687456A (zh) 2017-05-17
JP2020105189A (ja) 2020-07-09
BR112017005660A2 (pt) 2017-12-19
SG11201701915TA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
AU2015319724B2 (en) Novel soluble guanylate cyclase activators and their use
AU701127B2 (en) Muscarine antagonists
AU2014316690B2 (en) Novel soluble guanylate cyclase activators and their use
EP3630749B1 (en) 2-quinolone derived inhibitors of bcl6
TW202229253A (zh) Tlr7/8拮抗劑及其用途
ES2548134T3 (es) Derivados de piperidina 3,4-sustituida como inhibidores de renina
JP2023551110A (ja) Ｉｌ‐１７モジュレーターとしてのジシクロプロピルメチル誘導体
EP3480193A1 (en) Novel pyrazole derivative as alk5 inhibitor and uses thereof
AU2022229939A1 (en) Benzo[c][2,6]naphthyridine derivatives, compositions and therapeutic uses thereof
WO2023040998A1 (en) A cyclin-dependent kinase inhibitor
EP4482587A1 (en) Emopamil-binding protein inhibitors and uses thereof
CA2804924A1 (en) Substituted pyridine compound
KR20250073643A (ko) Parg 억제 화합물
WO2025073870A1 (en) Parg inhibitory compound
CN105980373A (zh) 新的可溶性鸟苷酸环化酶活化剂及它们的用途

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211209

FZDE Discontinued

Effective date: 20211209